

# Chest CT in the evaluation of chronic obstructive pulmonary disease: recommendations of Asian Society of Thoracic Radiology

Li Fan, MD<sup>\*1</sup>, Joon Beom Seo, MD, PhD<sup>2</sup>, Yoshiharu Ohno, MD, PhD<sup>3,4</sup>, Sang Min Lee, MD, PhD<sup>2</sup>, Kazuto Ashizawa, MD, PhD<sup>5</sup>, Ki Yeol Lee, MD, PhD<sup>6</sup>, Qi Yang, MD<sup>7</sup>, Wiwatana Tanomkiat, MD<sup>8</sup>, Công Cung Văn, MD<sup>9</sup>, Trung Hieu Hoang, MD<sup>10</sup>, Shi Yuan Liu, MD<sup>\*1</sup>, Jin Mo Goo, MD, PhD<sup>\*11</sup>; on behalf of Asian Society of Thoracic Radiology (ASTR)

<sup>1</sup>Department of Radiology, Second Affiliated Hospital, Naval Medical University, Shanghai, 200003, China

<sup>2</sup>Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 05505, South Korea

<sup>3</sup>Department of Diagnostic Radiology, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan

<sup>4</sup>Joint Research Laboratory of Advanced Medical Imaging, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan

<sup>5</sup>Department of Clinical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8523, Japan

<sup>6</sup>Department of Radiology, Korea University Guro Hospital, Korea University of Medicine, Seoul, 08380, South Korea

<sup>7</sup>Beijing Chao-yang Hospital, Capital Medical University, Beijing, 100013, China

<sup>8</sup>Department of Radiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, 90110, Thailand

<sup>9</sup>Department of Imaging Diagnosis, Vietnam National Lung Hospital, Hanoi, 100000, Vietnam

<sup>10</sup>Department of Radiology, Hue University of Medicine and Pharmacy, Hue University, Hue, 530000, Vietnam

<sup>11</sup>Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, 03080, Korea

\*Corresponding authors: Li Fan, MD, Department of Radiology, Second Affiliated Hospital, Naval Medical University, No. 415 Fengyang Road, Shanghai, 200003, China (fanli0930@163.com), Shi Yuan Liu, MD, Department of Radiology, Second Affiliated Hospital, Naval Medical University, No. 415 Fengyang Road, Shanghai, 200003, China (cjr.liushiyuan.vip@163.com) and Jin Mo Goo, MD, PhD, Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, 03080, Seoul, Korea (jimgoo@snu.ac.kr)

## Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a significant public health challenge globally, with Asia facing unique burdens due to varying demographics, healthcare access, and socioeconomic conditions. Recognizing the limitations of pulmonary function tests in early detection and comprehensive evaluation, the Asian Society of Thoracic Radiology presents this recommendations to guide the use of chest computed tomography (CT) in COPD diagnosis and management. This document consolidates evidence from an extensive literature review and surveys across Asia, highlighting the need for standardized CT protocols and practices. Key recommendations include adopting low-dose paired respiratory phase CT scans, utilizing qualitative and quantitative assessments for airway, vascular, and parenchymal evaluation, and emphasizing structured reporting to enhance clinical decision-making. Advanced technologies, including dual-energy CT and artificial intelligence, are proposed to refine diagnosis, monitor disease progression, and guide personalized interventions. These recommendations aim to improve the early detection of COPD, address its heterogeneity, and reduce its socioeconomic impact by establishing consistent and effective imaging practices across the region. This recommendations underscore the pivotal role of chest CT in advancing COPD care in Asia, providing a foundation for future research and practice refinement.

**Keywords:** chronic obstructive pulmonary disease; CT; pulmonary function test.

## Introduction

Chronic obstructive pulmonary disease (COPD) is a major public health issue of global concern. According to the World Health Organization (WHO), COPD is the third leading cause of death worldwide, affecting approximately 213 million people and imposing a profound burden on healthcare systems and economies. Over half of COPD cases and 68% of COPD-related deaths and disability-adjusted life-years occurred in low- and middle-income countries.<sup>1</sup> In 2019, China bore the largest COPD death toll in absolute terms, followed by India and the United States.<sup>2</sup> South Korea had the highest

COPD death rate, followed by Nepal, Denmark, and China.<sup>2</sup> Among World Bank regions, the macroeconomic burden of COPD was highest in East Asia and Pacific. East Asia and Pacific and south Asia were projected to experience the second-largest and third-largest percentage losses by 2050, respectively.<sup>2</sup> The low awareness rate of COPD among the Chinese population (only 0.9%) has directly led to delays in early diagnosis and treatment. When the disease is diagnosed, it is often in the advanced stage, the corresponding poor efficacy and prolonged course of disease can greatly increase the medical expenses of patients and socio-economic burden.<sup>3</sup>

Received: 4 January 2025; Revised: 16 May 2025; Accepted: 21 May 2025

© The Author(s) 2025. Published by Oxford University Press on behalf of the British Institute of Radiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [reprints@oup.com](mailto:reprints@oup.com) for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

Similarly, Korea and Japan, 2 other economically advanced countries in Asia, face significant COPD challenges. In Korea, the prevalence of COPD has been rising steadily, fueled by historical smoking habits and an aging population.<sup>4</sup> The economic impact of COPD in Korea is substantial, with both direct and indirect costs contributing to the overall burden. Japan, renowned for its advanced healthcare system, still faces significant challenges in managing COPD. The disease's prevalence is on the rise, primarily due to the aging population and high prevalence of smoking, particularly among men.<sup>5</sup> Expect for aging and smoking, air pollution, infections, tuberculosis as a confounder, and cor pulmonale is also the high risk factor for COPD.

Pulmonary function test (PFT) is currently the gold standard for clinical diagnosis of COPD. However, the sensitivity of early diagnosis is not high, and usually abnormalities occur only when the lung structure is damaged by more than 30%, and cannot reflect the heterogeneity of COPD.<sup>6</sup> In addition, the single threshold diagnostic criterion for PFT (FEV1/FVC) <0.70 after using bronchodilators can lead to over diagnosis in the elderly and missed diagnosis in the young population.<sup>7</sup> Since the 2022 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines pointing out that attention should be paid to the prevalence of COPD among people aged 20-50. Due to the low awareness of COPD among young people and the frequent missed diagnosis of COPD among young people, it is necessary to strengthen the screening of COPD and pre-COPD in young people. Pre-COPD refers to the occurrence of respiratory symptoms at any age group, with or without lung structural damage and/or abnormal lung function, without airflow restriction, but chest CT may present with emphysema. Therefore, international and domestic experts have appealed to attach importance to the comprehensive evaluation of structural quantification and functional imaging of COPD, as well as to the establishment of more sensitive diagnostic methods and quantitative indicators for patients with pre-COPD.<sup>8-10</sup>

COPD is a heterogeneous lesion that can undergo remodeling of small pulmonary vessels and airways as the disease progresses, leading to the formation of emphysema. Chest CT could not only evaluate the damage of lung function with the degree of emphysema, the morphological and structural change of large and small airways in patients with COPD but also evaluate the severity of COPD, then, could predict the risk of acute exacerbation by quantifying the changes of lung parenchyma, airways, and pulmonary vessels. Paired respiratory phases CT (end inspiratory and end expiratory CT) is used to detect air trapping, distinguish emphysema from air trapping, achieve early diagnosis and personalized evaluation of COPD, guiding treatment and management. Therefore, there are many advantages of Chest CT for the COPD accurate, quantitative and focal evaluation on the aspect of lung density, small airway and pulmonary vessels in comparison with PFT. However, current clinical practice does not pay enough attention to this aspect. Quantitative analysis of chest CT mainly focuses on evaluating pulmonary nodules, while the analysis of emphysema mainly focuses on subjective qualitative evaluation. There is still a lack of consistent agreement of chest CT scanning methods and evaluations for COPD.

Therefore, the Asian Society of Thoracic Radiology (ASTR) takes the lead in organizing experts to discuss and compile the "Current Status in Asia and Recommendations of

Asian Society of Thoracic Society on Chest CT Examination and Evaluation of Chronic Obstructive Pulmonary Disease" with reference to the current diagnosis and treatment status of COPD in the world and Asian clinical practice of chest CT, aiming to guide medical institutions to standardize the chest CT scanning scheme and CT-based qualitative and quantitative evaluation, to improve the early diagnosis and evaluation of COPD.

## Organization and methods

### Committee composition

The working group comprised thoracic radiologists with expertise in COPD who volunteered to contribute to report the current status of Asia since the 2023 ACTI held in Seoul, South Korea. The Executive Committee members of the ASTR volunteered to be part of this initiative.

### Generating recommendations

The working group first performed the systemic literature search published by the Asian, then, made the clinical practice and research survey in the Asia through ASTR. A tentative list of recommendations was circulated among the working group members to discuss, continuing until consensus was achieved. The recommendation document, along with supporting materials, was sent to all the working group members via e-mail to finalize the consensus.

To understand the current status of the clinical practice and research about chest CT for the evaluation of COPD in Asia, the working group has retrieved the following datasets including PubMed, Cochrane Library, Embase, and Web of Science for a systematic literature search. All original articles published by the Asia in English before September 30, 2024 were searched. The retrieved key words were showed in Table 1. All the literatures were reviewed by 2 thoracic radiologists and evaluated the method of each literature. A total of 140 papers were finally included, published by China 39, South Korea 39, Japan 56, India 3, Turkey 1, Malaysia 1, and Vietnam 1. We have made the literature analysis on the aspect of chest CT scanning technique, respiratory phase, visual and quantitative evaluation parameters, and AI related work.

Based on the literature, the working group then designed the survey for COPD Chest CT scanning and evaluation in the Asian countries and regions.

### Results of literature review and survey

Table 2 showed the detailed current status of chest CT for COPD evaluation in Asia from the aspect of respiratory phase, CT radiation dose, reconstruction algorithms, reconstruction slice thickness, evaluation parameters, and clinical topics.

Table 3 showed the survey results from China, South Korea, Japan, Vietnam, and Thailand for COPD in the clinical practice and research.

## List of recommendations

### CT indications

GOLD 2024 recommend chest CT for COPD patients with persistent exacerbation, symptoms out of proportion to disease severity on lung function testing, FEV1 less than 45% predicted with significant hyperinflation and gas trapping,

**Table 1.** Keywords for the systemic literature search about COPD with CT.

|             |                                        |
|-------------|----------------------------------------|
| Keyword 1   | Pulmonary disease, chronic obstructive |
| Free word 1 | COPD                                   |
|             | Chronic Obstructive Pulmonary Disease  |
|             | COAD                                   |
|             | Chronic Obstructive Airway Disease     |
|             | Chronic Obstructive Lung Disease       |
|             | Airflow Obstruction, Chronic           |
|             | Airflow Obstructions, Chronic          |
|             | Chronic Airflow Obstructions           |
|             | Chronic Airflow Obstruction            |
| Keyword 2   | Tomography, X-Ray Computed             |
| Free word 2 | X-Ray Computed Tomography              |
|             | Tomography, X-Ray Computerized         |
|             | Tomography, X Ray Computerized         |
|             | Computed X Ray Tomography              |
|             | X-Ray Computer Assisted Tomography     |
|             | X Ray Computer Assisted Tomography     |
|             | Tomography, X-Ray Computer Assisted    |
|             | Tomography, X Ray Computer Assisted    |
|             | Computerized Tomography, X Ray         |
|             | Computerized Tomography, X-Ray         |
|             | X-Ray Computerized Tomography          |
|             | CT X Ray                               |
|             | CT X Rays                              |
|             | X Ray, CT                              |
|             | X Rays, CT                             |
|             | Tomodensitometry                       |
|             | Tomography, X Ray Computed             |
|             | X Ray Tomography, Computed             |
|             | X-Ray Tomography, Computed             |
|             | Computed X-Ray Tomography              |
|             | Tomographies, Computed X-Ray           |

or for those who meet criteria for lung cancer screening (\*adapted from GOLD 2024).

Other clinical scenarios suggest to consider chest CT:

- 1) COPD patients confirmed on PFT but in situations to rule out comorbidities such a lung cancer, or ILD;
- 2) Patients with high risk or clinically suspected of COPD but are unable to do PFT;
- 3) Patients with high risk or clinically suspected of COPD but in caring units that PFT is not available;
- 4) Patients with high risk or clinically suspected of COPD but negative on PFT. (Considering the advantages of chest CT is more sensitive in detection of emphysema than PFT, CT should be performed in PFT-negative patients with dyspnea, chronic cough, or expectoration, or a history of recurrent lower respiratory tract infection and/or exposure to risk factors of the disease, aiming the early screening of COPD.)

**CT scanning recommendations**

Based on the current status of Chest CT for COPD in clinical practice and research (Tables 2 and 3), we recommend the standard dose, low-dose chest CT protocols, and respiratory phases for different population cohorts based on the GOLD 2024 population classification with PFTs.

**Standard dose CT protocol**

At least 64 multidetector CT (64-MDCT) with spiral scanning is recommended. Tube voltage 120 kVp, Dose modulation or automatic tube current modulation technology,

Collimation  $\leq 1.25$  mm; Reconstruction thickness  $\leq 1.25$  mm (1 mm is optical), Reconstruction interval: no interval or 80% of the thickness depending on the thickness is 0.625 mm or thicker, Scan matrix  $512 \times 512$ , Reconstruction algorithm or filter function with standard algorithm and lung algorithm reconstruction; Reconstruction mode: FBP or iterative reconstruction; Lung window setting level  $-600$  to  $-650$ HU, window width 1500-1600HU; Mediastinal window setting level 40-50HU, window width 350-380HU.

**Low dose CT protocol**

If CT has iterative reconstruction technology, 120 kVp and less than 30 mAs could be used as scanning parameters; If CT does not have iterative reconstruction technology, the fixed scanning parameters of 120 kVp, 30-50 mAs could be considered.

**Inspiratory and expiratory phase**

- For patients with confirmed COPD, recommended to perform standard dose or low dose Chest CT scanning with paired respiratory phases.
- For middle-aged and elderly people with suspected COPD but insufficient diagnostic criteria or at high risk, low dose chest CT scanning with paired respiratory phases is recommended.
- For young people aged 20-40 years who have a history of premature infants, childhood asthma, or childhood respiratory tract infections, a family history of respiratory system diseases, or smoking, passive smoking, steam, or electronic cigarettes, recommended to perform low-dose chest CT scans only on the end of inspiration.

**Comment**

Radiation dose is very important for the pulmonary lesion detection and accurate diagnosis. There are many studies focusing the scanning technique of chest CT of patients and phatoms. Quantitative Imaging Biomarkers Alliance (QIBA) lung density profile has recommended the scanning protocol with standard and low dose CT for different vendors. Based on QIBA, 120 KV is recommended for both standard and low dose CT. For low dose CT, the mAs varied from 35 to 50 mAs. Dose modulation or automatic tube current modulation technology, and iterative reconstruction (noise reduction) is also recommended in QIBA. It has been reported that a combination of volume adjustment and noise reduction filtering improved the reproducibility of lung density measurements computed using serial full dose (200 mAs) and reduced dose (40-80 mAs varied owing to dose modulation) CT scans.<sup>177</sup> Acquisition and reconstruction methods are significantly affecting radiation dose reduction and accuracy of CT number measurements on a phantom study by Ohno et al.<sup>178</sup> It has been proven that low dose CT protocol at 50 mAs on 64-detector row CT scanner can produce the screening results consistent with standard dose CT protocol (150 mAs), supporting routine use of low dose chest CT protocol.<sup>179</sup> Other studies also showed low dose chest CT scanning does not affect the quantitative analysis of lung density based on iterative reconstruction algorithms.<sup>25</sup> To give consideration to the accuracy of subjective qualitative evaluation and objective quantitative evaluation, it is recommended to adopt a consistent scanning scheme for paired respiratory phases scanning for middle-aged and elderly people.

**Table 2.** Current status of chest CT for COPD evaluation in Asia.

| Country                           | China ( <i>n</i> = 69)                                                                           | South Korea ( <i>n</i> = 39)                                          | Japan ( <i>n</i> = 62)                                                                                     | India ( <i>n</i> = 3) | Turkey ( <i>n</i> = 1) | Malaysia ( <i>n</i> = 1) | Vietnam ( <i>n</i> = 1) |
|-----------------------------------|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|-----------------------|------------------------|--------------------------|-------------------------|
| <b>Scanning respiratory phase</b> |                                                                                                  |                                                                       |                                                                                                            |                       |                        |                          |                         |
| Inspiratory                       | 41 <sup>11,51</sup>                                                                              | 12 <sup>52-63</sup>                                                   | 15 <sup>64-79</sup>                                                                                        | 3 <sup>80-82</sup>    |                        |                          | 1 <sup>83</sup>         |
| Paired respiratory                | 18 <sup>64,84-100</sup>                                                                          | 15 <sup>65,101-114</sup>                                              | 16 <sup>115-130</sup>                                                                                      |                       |                        | 1 <sup>131</sup>         |                         |
| <b>Standard or reduced dose</b>   |                                                                                                  |                                                                       |                                                                                                            |                       |                        |                          |                         |
| 120 kVp/140 kVp/50-120 mA         | 14 <sup>13,20,23,28,34,41,42,47,89,91,97,99,132,133</sup>                                        | 18 <sup>53,55,57,63,65,102,104-106,108-111,113,114,131,134-136</sup>  | 16 <sup>66,75,116,124,127-129,139-147</sup>                                                                |                       | 1 <sup>137</sup>       |                          |                         |
| 140-150 mA                        | 5 <sup>30,37,43,50,138</sup>                                                                     | 5 <sup>59,107,112,148,149</sup>                                       | 2 <sup>125,151</sup>                                                                                       |                       |                        |                          |                         |
| 150-220 mA                        | 8 <sup>12,18,24,26,31,38,46,51</sup>                                                             |                                                                       | 22 <sup>67,71,76-79,115,119-123,126,130,152-156</sup>                                                      |                       |                        |                          |                         |
| 250-440 mA                        | 5 <sup>16,44,85,86,150</sup>                                                                     | 1 <sup>152</sup>                                                      |                                                                                                            |                       |                        |                          |                         |
| Tube current modulation           | 6 <sup>15,29,38,88,92,93</sup>                                                                   |                                                                       |                                                                                                            |                       |                        |                          |                         |
| <b>Low-dose</b>                   |                                                                                                  |                                                                       |                                                                                                            |                       |                        |                          |                         |
| 110 kV/120 Kv, 20-50 mA           | 14 <sup>11,21,25,27,36,39,40,44,49,84,90,94,96,98</sup>                                          | 3 <sup>54,157,158</sup>                                               |                                                                                                            |                       |                        |                          |                         |
| 70,80, 90 KV, Sn100 kV            | 4 <sup>48,150,159,160</sup>                                                                      |                                                                       |                                                                                                            |                       |                        |                          |                         |
| <b>Reconstruction thickness</b>   |                                                                                                  |                                                                       |                                                                                                            |                       |                        |                          |                         |
| ≤1 mm                             | 44 <sup>11,15-23,25,27-29,31,34,36,38-40,43-49,84,86,88,89,91-93,96-99,132,133,138,159-161</sup> | 24 <sup>52,54-57,63,101,102,104-106,108-114,131,134-136,157,158</sup> | 37 <sup>67-72,75,76,78,79,87,115-117,119-122,124-127,130,139,141,144,145,147,151,152,154-156,162-165</sup> | 2 <sup>80,82</sup>    |                        | 1 <sup>131</sup>         | 1 <sup>83</sup>         |
| >1 mm                             | 12 <sup>12-14,24,35,37,50,51,85,94,150,161,166</sup>                                             | 7 <sup>53,54,59,61,65,103,149</sup>                                   | 10 <sup>66,87,123,128,142,143,145-147,153</sup>                                                            | 1 <sup>81</sup>       | 1 <sup>137</sup>       |                          |                         |
| <b>Reconstruction algorithm</b>   |                                                                                                  |                                                                       |                                                                                                            |                       |                        |                          |                         |
| Standard algorithm                | 19 <sup>12,15,17-20,23-26,28,29,64,86,94,98,99,159,161</sup>                                     | 17 <sup>53,55,56,102,103,106,108-114,131,134,135,158</sup>            | 11 <sup>71,87,116,117,125,127,129,147,154,164,165</sup>                                                    |                       | 1 <sup>137</sup>       | 1 <sup>131</sup>         |                         |
| Lung algorithm                    | 6 <sup>11,42,89,90,93,96,139</sup>                                                               | 4 <sup>54,59,65,105</sup>                                             | 8 <sup>66,67,75,77-79,146,156</sup>                                                                        |                       |                        |                          |                         |
| Lung/standard algorithm           | 1 <sup>132</sup>                                                                                 |                                                                       | 1 <sup>70</sup>                                                                                            |                       |                        |                          |                         |
| Others                            | 1 <sup>21</sup>                                                                                  | 5 <sup>54,106,109,148,167</sup>                                       | 3 <sup>73,115,164</sup>                                                                                    |                       |                        |                          |                         |
| <b>Visual evaluation</b>          | 2 <sup>23,91</sup>                                                                               |                                                                       | 5 <sup>129,140,141,147,168</sup>                                                                           |                       |                        |                          |                         |

(continued)

Table 2. (continued)

| Country                    | China (n = 69)                                                                                    | South Korea (n = 39)                                           | Japan (n = 62)                                                                                   | India (n = 3)      | Turkey (n = 1)   | Malaysia (n = 1) | Vietnam (n = 1) |
|----------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------|------------------|------------------|-----------------|
| Quantitative evaluation    |                                                                                                   |                                                                |                                                                                                  |                    |                  |                  |                 |
| Emphysema                  | 35 <sup>12,14,15,20,21,24-29,32-34,36,42,43,45,46,49,85,86,88,90-92,94,95,97-99,132,133,161</sup> | 27 <sup>52-59,62,63,65,102-114,131,167,169</sup>               | 30 <sup>64,66,68,70,73,74,76-79,87,115,118,120-126,128,139,144,146,151,152,154,155,164,170</sup> | 2 <sup>80,82</sup> | 1 <sup>137</sup> | 1 <sup>131</sup> | 1 <sup>83</sup> |
| Blood vessels              | 8 <sup>13,18,21,22,30,49,50,133,138</sup>                                                         | 4 <sup>52,57,110,148</sup>                                     | 7 <sup>68,71,72,127,139,145,146</sup>                                                            |                    |                  | 1 <sup>131</sup> |                 |
| Distal small airway        | 20 <sup>12,14,15,17,20,21,27,29,42,48,86,90-92,96,97,132,133,159,161</sup>                        | 7 <sup>57,101,105,107,109,131,171</sup>                        | 24 <sup>64,66,71,73,75-77,79,115,116,118-121,139,144,151,154,156,162,164,165,170,172</sup>       |                    |                  |                  |                 |
| Mucus secretion            |                                                                                                   | 1 <sup>60</sup>                                                | 2 <sup>121,122</sup>                                                                             |                    |                  |                  |                 |
| PRM                        | 5 <sup>45,89,91,92,133</sup>                                                                      | 4 <sup>102,104,106,169</sup>                                   | 6 <sup>115,116,118,121,125,130</sup>                                                             |                    |                  |                  |                 |
| Lung ventilation/perfusion | 1 <sup>160</sup>                                                                                  | 4 <sup>59,61,65,101</sup>                                      | 1 <sup>126</sup>                                                                                 |                    |                  |                  |                 |
| Topic                      |                                                                                                   |                                                                |                                                                                                  |                    |                  |                  |                 |
| CT technique               | 20 <sup>18,21,25,26,28,30,33,34,42,47,84,86,90,92,99,115,133,138,150,159</sup>                    | 14 <sup>52,54,56,58,59,62,65,101,102,106,110,112,113,135</sup> | 6 <sup>129,147,152,155,163,165</sup>                                                             |                    |                  |                  |                 |
| Diagnosis                  | 22 <sup>13,15,16,23,31,35,36,38-41,43,88,89,91,96,97,101,132,173-176</sup>                        | 10 <sup>53,55,57,103,111,114,148,149,158,167</sup>             | 6 <sup>78,94,120,143,151,168</sup>                                                               |                    |                  |                  |                 |
| Severity                   | 12 <sup>13,16,22,37,48-51,95,100,132,175</sup>                                                    | 1 <sup>111</sup>                                               |                                                                                                  | 2 <sup>80,81</sup> |                  |                  |                 |
| Acute exacerbation         | 5 <sup>12,22,29,45,46</sup>                                                                       | 1 <sup>60</sup>                                                | 1 <sup>72</sup>                                                                                  |                    |                  |                  |                 |
| Survival                   | 1 <sup>24</sup>                                                                                   | 8 <sup>54,107,108,131,134,136,158,171</sup>                    | 4 <sup>64,74,77,142</sup>                                                                        |                    |                  | 1 <sup>131</sup> |                 |
| Phenotype                  | 4 <sup>11,33,94,161</sup>                                                                         | 1 <sup>109</sup>                                               | 5 <sup>73,87,141,155,164</sup>                                                                   |                    |                  |                  |                 |
| Treatment response         | 1 <sup>19</sup>                                                                                   | 1 <sup>136</sup>                                               |                                                                                                  |                    |                  | 1 <sup>131</sup> |                 |
| Radiomics                  | 13 <sup>16,35,36,38-41,45-47,51,92,150</sup>                                                      |                                                                |                                                                                                  |                    |                  |                  |                 |
| AI                         | 19 <sup>19,35,36,38-41,45-47,51,92,132,138,150,173-176</sup>                                      | 9 <sup>52,56,102,135,148,157,158,167,169</sup>                 | 2 <sup>67,79</sup>                                                                               |                    |                  |                  |                 |

**Table 3.** Imaging evaluation of COPD survey in Asia.

|                                                     | China                                                   | Japan                                                                       | South Korea                                                  | Vietnam                            | Thailand      | Comment |
|-----------------------------------------------------|---------------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------|------------------------------------|---------------|---------|
| General awareness of COPD                           | 0.9%                                                    | 10%-30%                                                                     | 31.6%                                                        | 10%-30%                            | 10%-30%       |         |
| Chest CT for COPD screening                         | Yes                                                     | Yes                                                                         | No, perform if clinicians need to evaluate                   | No, perform when doctors indicates | No            |         |
| Chest CT for lung cancer screening                  | Yes                                                     | Yes                                                                         | Yes                                                          | Yes                                | Yes           |         |
| Smoking rate                                        | 24.1%                                                   | 16.7%                                                                       | 17.7%                                                        | 10%                                | 10%           |         |
| Prevalence of COPD                                  | 13.7% ( $\geq 40$ y)                                    | 8.6% ( $\geq 40$ y)                                                         | 10.8% ( $\geq 40$ y)                                         | 10%                                | 7%            |         |
| Prevalence of lung cancer                           | Man: 91.36                                              | Man: 137.3                                                                  | Man: 71.73                                                   | Man: 34                            | Man: 32       |         |
| ( $n/100\ 000$ )                                    | Woman: 58.18                                            | Woman: 65.2                                                                 | Woman: 50.02                                                 | Women: 10                          | Women: 10     |         |
| Subjective evaluation in clinical work?             | 1, 2, 3, 4, 5                                           | 1, 2, 3, 4, 5                                                               | 1, 2, 3, 4, 5                                                | 1, 2, 3, 4, 5                      | 1, 2, 3, 4, 5 |         |
| 1) Emphysema                                        |                                                         |                                                                             |                                                              |                                    |               |         |
| 2) Airway wall thickening                           |                                                         |                                                                             |                                                              |                                    |               |         |
| 3) Mucus plug                                       |                                                         |                                                                             |                                                              |                                    |               |         |
| 4) Mosaic pattern                                   |                                                         |                                                                             |                                                              |                                    |               |         |
| 5) D main pulmonary artery/D descending aorta $> 1$ |                                                         |                                                                             |                                                              |                                    |               |         |
| Lung volume analysis                                | Analysis level                                          | Lobe level                                                                  | Lobe level                                                   | Lobe level                         | No            | No      |
|                                                     | Clinic or research use                                  | Both                                                                        | Both                                                         | Both                               | No            | No      |
| Lung density analysis                               | Analysis level                                          | Lobe level                                                                  | Lobe level                                                   | Lobe level                         | No            | No      |
|                                                     | Emphysema analysis                                      | Yes                                                                         | Yes                                                          | Yes                                | No            | No      |
|                                                     | Air trapping analysis                                   | Yes                                                                         | Yes                                                          | Yes                                | No            | No      |
|                                                     | PRM analysis                                            | Yes                                                                         | Yes                                                          | Yes                                | No            | No      |
|                                                     | Clinic or research use                                  | Both                                                                        | Both                                                         | Both                               | No            | No      |
| Airway analysis                                     | Generation of airway                                    | 6th                                                                         | 8-10th                                                       | 6-8th                              | No            | No      |
|                                                     | standardized airway                                     | Yes                                                                         | Yes                                                          | Yes                                | No            | No      |
|                                                     | wall thick-<br>ness parameter                           |                                                                             |                                                              |                                    |               |         |
|                                                     | total airway counting                                   | Yes                                                                         | No                                                           | Yes                                | No            | No      |
|                                                     | Clinic or research use                                  | Both                                                                        | Research                                                     | Both                               | No            | No      |
| Lung vessels analysis                               | small vessel analysis                                   | Yes                                                                         | No                                                           | Yes                                | No            | No      |
|                                                     | (CSA 5 mm <sup>2</sup> , or<br>CSA 10 mm <sup>2</sup> ) |                                                                             |                                                              |                                    |               |         |
|                                                     | Clinic or research use                                  | Research                                                                    | No                                                           | Research                           | No            | No      |
| Do you plan to perform COPD quantification?         | Yes                                                     | No for daily<br>clinical practice, for some clinical<br>but do for research | Already in use<br>for some clinical practice<br>and research | Yes                                | Yes           |         |

### CT qualitative evaluation recommendations

A comprehensive evaluation of the condition of emphysema, airways, and blood vessels is suggested. It is recommended to indicate the specific type and severity of emphysema, and evaluate the severity using a semi-quantitative method (Table 4). The presence of mucus plug in the airway and air trapping is suggested to evaluate. For those diagnosed with COPD, the imaging phenotype and the possibility of pulmonary hypertension is recommended to evaluate guiding clinical treatment. The qualitative evaluation flowchart is shown in Figure 1.


**Comment** According to the Fleischner Association Recommendation,<sup>180</sup> the types of emphysema are divided into 3 types: centrilobular type (CLE), panlobular type, and Para septal type (Figures 1 and 2); CLE emphysema is further divided into minimal CLE (very small lobular central type transparent shadows, distributed less than 0.5% of the lung lobes), mild CLE (scattered lobular central type transparent shadows, surrounded by normal lung tissue, accounting for 0.5% to 5% of the total lung lobes), moderate CLE (more clearly defined transparent shadows, more than 5% of the lung lobes), fusion CLE (aggregated centrilobular or lobar lucency, including multiple lucency occupying multiple secondary pulmonary lobules, but excluding significant expansion or distortion of secondary pulmonary lobules) and

**Table 4.** Subjective visual Goddard scoring method for emphysema.


| Goddard score | Proportion of emphysema in this cross-sectional anatomical layer (emphysema%) |
|---------------|-------------------------------------------------------------------------------|
| 0             | 0                                                                             |
| 1             | 0% < emphysema% $\leq$ 25%                                                    |
| 2             | 25% < emphysema% $\leq$ 50%                                                   |
| 3             | 50% < emphysema% $\leq$ 75%                                                   |
| 4             | 75% < emphysema% $\leq$ 100%                                                  |

Generally, 3 cross-sectional anatomical levels of both lungs are selected for evaluation: the upper lung level is the aortic arch level; The middle lung level is at the carina level; The lower lung level is about 1 cm above the top of the right diaphragm;<sup>15</sup> The 2 lungs are divided into 6 anatomical layers, with 0-4 points for each anatomical layer, and a total score of 0-24 points; Mild, total score  $\leq 8$  points; Moderate, 8 points < total score  $\leq 16$  points; Severe, total score  $> 16$  points.

progressive destruction (accompanied by expansion and distortion of secondary pulmonary lobules). Panlobular emphysema is extremely rare in our population. The subjective visual Goddard scoring method can be used to assess the severity of emphysema (Table 2), which is particularly suitable for units without quantitative analysis software for emphysema. Airway morphology mainly includes thickening of segmental and subsegmental bronchial walls, inflammatory small airway diseases and obstructive small airway diseases,




**Figure 1.** Flowchart for qualitative evaluation of Chest CT for COPD.



**Figure 2.** CT images of chronic obstructive pulmonary disease (COPD). (A) Shows the type of emphysema as centrilobular type, and (B) shows the type of emphysema as paraseptal type; (C) and (D) show air trapping in the lower lobes of both lungs in the inspiratory phase and expiratory phase respectively; (E-G) shows the different imaging phenotypes of COPD, (E) shows Type A, (F) shows Type E, and (G) shows Type M; (H) shows COPD with pulmonary hypertension, with a diameter ratio of the main pulmonary artery to the ascending aorta at the same level greater than 1.

the presence or absence of mucus plug in the airway, and the specific location of the tracheobronchial tree where they exist; Through the comparison of paired respiratory phases CT images, evaluate whether there is air trapping and the involved range (Figure 3). Due to the correlation between imaging phenotypes and clinical grading and treatment improvement, it is particularly important to determine imaging phenotypes. The commonly used imaging phenotypes include the following: Type A, without or with mild emphysema, regardless of the presence of bronchial wall thickening; Type E, with significant emphysema and no thickening of the bronchial wall; Type M, with significant emphysema and bronchial wall thickening.<sup>181</sup> Pulmonary vascular changes mainly include pulmonary arterial hypertension caused by pulmonary vascular remodeling, which

ultimately leads to ventricular remodeling and pulmonary heart disease, characterized by widening of the pulmonary artery and enlargement of the right atrium and ventricle. The diameter of the main pulmonary artery and its ratio to the diameter of the ascending aorta at the same level on the inspiratory phase CT image are often evaluated. If the diameter of the main pulmonary artery is greater than 29 mm, and the diameter ratio of the main pulmonary artery to the diameter of the ascending aorta at the same level is greater than 1, it indicates that there is a greater possibility of secondary pulmonary hypertension. CT scanning radiation dose and reconstruction mode is important for the qualitative evaluation of chest CT images. IR is useful for image noise reduction and provides better image quality. With AIDR 3D assessment of radiologic findings obtained with reduced-(50 mAs) and low-dose



**Figure 3.** Flowchart for quantitative evaluation of Chest CT for COPD.

CT(25 mAs) for patients with various pulmonary diseases, the intermethod agreements for emphysema, bronchiectasis were almost perfect ( $\kappa > 0.81$ ) with the standard dose (150 mAs).<sup>182</sup> Visual ranking of 10 different mAs settings from 10 mAs to 100 mAs in 10 mAs increments, found that simulated dose levels below 60 mAs ( $=42$  mAs<sub>eff</sub>) were clearly differentiated from higher dose levels by 3 readers.<sup>183</sup> It has been reported that reduced-dose (50 mAs) MDCT had a potential of substitution for standard-dose MDCT (150 mAs) on the visual assessment of emphysema in pulmonary emphysema patients.<sup>184</sup>

### CT quantitative evaluation recommendation

For paired respiratory phases scanning, it is recommended to conduct at least quantitative evaluation of emphysema, large airway, air trapping, the ratio of main pulmonary artery diameter to ascending aorta diameter at the same level. Quantitative evaluation of functional small airways and blood vessels is suggested based on the functional status of the postprocessing software of each unit, as conditions permit. The quantitative evaluation process is shown in Figure 3. The parameters in the box are the minimum recommended measurement parameters.

**Comment** Chest CT quantitative evaluation has important clinical value in the early diagnosis, severity evaluation, phenotype analysis, and accurate identification of target lung tissue in lung volume reduction surgery for COPD.<sup>74,136,185-190</sup> CT quantitative evaluation combined with clinical basic information, clinical comprehensive evaluation scale, and PFT has great potential in the evaluation and prediction of acute exacerbation of COPD, readmission prediction, prediction of rapid decline in lung function, survival prediction and prognosis analysis, and prediction of complications. Quantitative evaluation is very important for the prediction of adverse events in COPD. Research has confirmed that partial naked eye observation of normal chest CT can be used for early diagnosis of emphysema through quantitative evaluation of CT lung density. For example, in the screening of lung cancer in Shanghai, the subjective evaluation of people over 60 years of

age is normal, and through quantitative evaluation of CT, it is found that 8.3% of them have emphysema.<sup>191</sup> Therefore, conducting CT quantitative evaluation of COPD has important clinical value.

Quantitative evaluation of chest CT includes quantitative evaluation of lung volume, emphysema, airway, and pulmonary small vessels. When performing quantitative evaluation of chest CT, it is first necessary to automatically or manually segment the left and right lungs. Currently, some software can automatically segment 5 lung lobes after modeling using artificial intelligence algorithms; then, the physician conducts a slice by slice review of the segmentation results. After the review is completed, a quantitative evaluation is performed, outputting the average lung density, emphysema volume and proportion, and regional differences in lung density for the entire lung, left lung, right lung, or each lung lobe. Finally, determine the presence, severity, and distribution of emphysema. On inspiratory chest CT, the percentage of lung tissue volume with a CT attenuation less than  $-950$  HU in the total lung volume is defined as the low attenuation area (LAA%) or emphysema index (EI). According to Fleischner's recommendation,  $EI \geq 6\%$  is defined as emphysema.<sup>180</sup> Small airway stenosis with diameter less than 2 mm is the main reason for COPD airflow restriction. However, because of its small diameter, most conventional CT images cannot be imaged or cannot be identified by the naked eye, so the degree of air trapping is often used to indirectly reflect the degree of small airway stenosis. End expiratory CT is the best method to evaluate COPD air trapping. Most studies quantitatively evaluate air trapping by evaluating the LAA% under the threshold of  $-856$  HU or  $-850$  HU (LAAexp-856 or LAAexp-850).

For paired respiratory CT images, after the left and right lungs are segmented, the quantitative analysis of air trapping can be carried out. The relevant parameters include the inspiratory to expiratory lung volume ratio, inspiratory to expiratory lung attenuation ratio, and inspiratory to expiratory relative volume changes of voxels with attenuation values between  $-860$  HU and  $-950$  HU at the whole lung, left and right

lungs, and even 5 lung lobe levels. Alternatively, perform parametric response map (PRM) analysis to evaluate the condition of functional small airway diseases. Specific parameters include the volume and percentage of PRM<sub>normal</sub>, PRM<sub>emphysema</sub>, and PRM<sub>fSAD</sub>.<sup>192-194</sup> Functional small airway disease is a transitional stage from normal lung parenchyma to emphysema. Early detection and intervention can reverse COPD. For a single inspiratory phase image, it is recommended to conduct at least a quantitative evaluation of the whole lung density, and the quantitative analysis of the lung lobe level depends on the specific configuration of each unit's postprocessing software. For paired respiratory images, it is recommended to conduct quantitative assessment of air trapping. The quantitative analysis of PRM depends on the specific configuration of post-processing software of each unit.

Large airway changes are also one of the phenotypes of COPD, mainly due to airway wall thickening and lumen narrowing. To quantitatively evaluate the airway and pulmonary vessels, it is necessary to first segment and extract the tracheobronchial bundle on the inspiratory phase to at least reach the sixth generation of bronchial tree, and then evaluate the quantitative parameters of the airway, including the thickness of the bronchial wall, the cross-sectional area of the bronchial wall, the area of the bronchial lumen, the diameter of the bronchial lumen, the percentage of the bronchial wall area (% WA), and the square root of the cross-sectional area of the bronchial wall with a circumference of 10 mm (Pi10). The changes of pulmonary vessels are closely related to the acute exacerbation of COPD, and the diameter of pulmonary artery significantly increases during the acute exacerbation of COPD. The quantitative parameters of pulmonary blood vessels based on CT plain scan include the diameter of the main pulmonary artery, the ratio of the diameter of the main pulmonary artery to the diameter of the ascending aorta at the same level, the number of pulmonary blood vessels in the whole lung, left and right lungs, and even at the level of 5 lobes, the cross-sectional area (CSA) of the pulmonary blood vessels, the percentage of CSA < 5 mm<sup>2</sup>, the surface area of the pulmonary blood vessels, and the average blood vessel diameter.<sup>49</sup>

Acquisition and reconstruction methods are significantly affecting radiation dose reduction and accuracy of CT number measurements, emphysema volume and airway wall thickness on a phantom study.<sup>178,195</sup> The use of adaptive iterative dose reduction using 3D processing resulted in greater consistency of emphysema quantification by low-dose CT, with quantification by standard-dose CT.

### Spectral CT imaging

Dual-energy CT (DECT) allows to the pulmonary ventilation and perfusion evaluation, which have important value in the early diagnosis, severity grading, and phenotype analysis of COPD. With the advent of DECT, pulmonary ventilation and perfusion imaging have become more convenient.<sup>26</sup> Energy CT enhanced scanning can obtain information such as iodine density maps that reflect pulmonary parenchyma perfusion, which has important reference significance for evaluating the heterogeneity and efficacy of blood perfusion in COPD.<sup>196</sup> In addition, energy CT imaging using xenon as a contrast agent after inhalation can be used to evaluate the ventilation function of COPD patients.<sup>196</sup>

For units with DECT, it is suggested to conduct functional imaging studies on COPD to provide more functional

information and evidence-based medical evidence for the diagnosis and treatment of COPD.

### Chest CT structure reporting recommendation

With the further improvement of quantitative evaluation of diseases, standardization of clinical diagnosis and treatment, and scientific research, structured reporting is the current trend of development. Quantitative and visual structured reports formed by extracting quantitative indicators of lung density, airway, and small blood vessels through artificial intelligence algorithms can provide more comprehensive quantitative data for clinical use and guide clinical treatment and follow-up management strategies. Currently, research on structured reports for quantitative analysis of COPD chest CT has been carried out in China. The implementation of structured reporting for COPD will contribute to the accurate evaluation of clinically assisted COPD.

### Recommendation for one-stop CT screening for COPD and lung cancer

COPD and lung cancer share the same high-risk factors, such as smoking, aging, and air pollution. COPD has also been proven the high risk for lung cancer. It has been recommended the chest Big 3 diseases (lung cancer, COPD, and cardiovascular disease) screening with Chest CT by the NELSON-China programs. Annual low dose CT is recommended for lung cancer screening in patients with COPD due to smoking according to recommendations for the general population (GOLD 2024).

### Perspective

With the development of CT technology and the progress of artificial intelligence algorithms, the CT quantitative evaluation of COPD in clinical practice would become more and more popular. Moreover, AI has show great potential for the COPD diagnosis, severity evaluation, prognosis prediction and management strategy with whole lung radiomics, deep learning and large language model. This recommendation will be gradually updated with the upgrade of CT hardware and post processing software, and the release of high-quality multi-center clinical research results, gradually establishing a more scientific and reasonable expert consensus.

In conclusion, this consensus establishes scanning protocols for different clinical scenarios. The qualitative and quantitative evaluation of lung density, airway, and small blood vessels by chest CT are of important guiding significance for the diagnosis, severity evaluation of COPD. Strengthening imaging evaluation of COPD and improving the level of understanding of COPD could reduce the socioeconomic burden.

### Acknowledgements

The authors would like to thank Dr. Taohu Zhou, MM, Jin Zhang, MM, Ziwei Zhang, MD, Xiuxiu Zhou, MM, Xin'ang Jiang, MM, Hanxiao Zhang, MM, Wenting Tu, MD, Xiang Wang, MM, Qianxi Jin, MM, Xiaoqing Lin, MM, Yi Wang, MM, Lin Zhu, MD, Di Zhang, MD, Yi Xia, MD, Yu Guan, MM, and Shuguang Xie, MM for literature search.

### Funding

This work was supported by the National Natural Science Foundation of China (Nos. 82430065, 82171926, and

82441012), the National Key Research and Development Program of China (Nos. 2022YFC2010002, 2022YFC2010000, 2022YFC2010005, and 2022YFC2010006), Excellent Health Sector Program of Shanghai Municipal Health Commission (20254Z0003) and Shanghai "Rising Stars of Medical Talent" Youth Development Program for Outstanding Youth Medical Talents (SHWSRS 2025-71).

## Conflicts of interest

J.M.G. research grants from Coreline Soft (related to the present article) and LG Electronics (not related to the present article), J.B.S. owns Stock from Coreline Soft (related to the present article) and Premedius (not related to the present article), and S.M.L. owns stock and research grants from Coreline Soft (related to the present article) and owns stock from Premedius (not related to the present article). Other authors declare no conflict of interest.

## References

- GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021. *Lancet*. 2024;403:2162-2203.
- Chen S, Kuhn M, Prettnner K, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study. *Lancet Glob Health*. 2023;11:e1183-e1193.
- Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet*. 2018;391:1706-1717.
- Yang B, Choi H, Lim JH, et al. The disease burden of bronchiectasis in comparison with chronic obstructive pulmonary disease: a national database study in Korea. *Ann Transl Med*. 2019;7:770.
- Kotaki K, Ikeda H, Fukuda T, et al. Trends in the prevalence of COPD in elderly individuals in an air-polluted city in Japan: a cross-sectional study. *Int J Chron Obstruct Pulmon Dis*. 2019;14:791-798.
- Agusti A, Calverley PMA, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. *Respir Res*. 2010;11:122.
- Miller MR, Levy ML. Chronic obstructive pulmonary disease: missed diagnosis versus misdiagnosis. *BMJ* 2015;351:h3021.
- Fan L, Xia Y, Guan Y, et al. Capability of differentiating smokers with normal pulmonary function from COPD patients: a comparison of CT pulmonary volume analysis and MR perfusion imaging. *Eur Radiol*. 2013;23:1234-1241.
- Keener A. Redefining the diagnostic criteria for COPD. *Nature*. 2020;581:S4-S6.
- Tanday S. Rethinking COPD diagnosis: imaging and GOLD criteria. *Lancet Respir Med*. 2015;3:605.
- He S-Z, He Q, Su Y-S, et al. Analysis of high-resolution computed tomography phenotypes and pulmonary function in chronic obstructive pulmonary disease. *J Int Med Res*. 2020;48:0300060519889459.
- Cheng T, Wan H, Cheng Q, et al. Computed tomography manifestation of acute exacerbation of chronic obstructive pulmonary disease: a pilot study. *Exp Ther Med*. 2016;11:519-529.
- Wang Y, Su T, Feng S, Chen J, Tian X, Zhu L. Evaluation of the cross-sectional area of small pulmonary vessels in the diagnosis of chronic obstructive pulmonary disease by quantitative computed tomography. *Medicine*. 2021;100:e27622.
- Gu S, Deng X, Li Q, Sun X, Xu J, Li H. Gender differences of chronic obstructive pulmonary disease associated with manifestations on HRCT. *Clin Respir J*. 2017;11:28-35.
- Wei X, Ding Q, Yu N, et al. Imaging features of chronic bronchitis with preserved ratio and impaired spirometry (PRISm). *Lung*. 2018;196:649-658.
- Li Z, Liu L, Zhang Z, et al. A novel CT-based radiomics features analysis for identification and severity staging of COPD. *Acad Radiol*. 2022;29:663-673.
- Li Y, Dai Y-L, Yu N, Guo Y-m. Sex-related differences in bronchial parameters and pulmonary function test results in patients with chronic obstructive pulmonary disease based on three-dimensional quantitative computed tomography. *J Int Med Res*. 2018;46:135-142.
- Yu N, Wei X, Li Y, Deng L, Jin C-w, Guo Y. Computed tomography quantification of pulmonary vessels in chronic obstructive pulmonary disease as identified by 3D automated approach. *Medicine*. 2016;95:e5095.
- Luo G, Lin A, Yang Z, Chen Y, Mo C, Abdulhay E. Computerized tomography image feature under convolutional neural network algorithm evaluated for therapeutic effect of clarithromycin combined with salmeterol/fluticasone on chronic obstructive pulmonary disease. *J Healthc Eng*. 2021;2021:8563181-8563111.
- Fei G, Tu Y-H, Zhang Y. The COPD assessment test correlates well with the computed tomography measurements in COPD patients in China. *Int J Chron Obstruct Pulmon Dis*. 2015;10:507-514.
- Tang G, Wang F, Liang Z, et al. Correlations of computed tomography measurement of distal pulmonary vascular pruning with airflow limitation and emphysema in COPD patients. *Int J Chron Obstruct Pulmon Dis*. 2022;17:2241-2252.
- Yang T, Chen C, Chen Z. The CT pulmonary vascular parameters and disease severity in COPD patients on acute exacerbation: a correlation analysis. *BMC Pulm Med*. 2021;21:34.
- Zhu D, Qiao C, Dai H, Hu Y, Xi Q. Diagnostic efficacy of visual subtypes and low attenuation area based on HRCT in the diagnosis of COPD. *BMC Pulm Med*. 2022;22:81.
- Cheng T, Wan HY, Cheng QJ, et al. Obvious emphysema on computed tomography during an acute exacerbation of chronic obstructive pulmonary disease predicts a poor prognosis. *Intern Med J*. 2015;45:517-526.
- Cao X, Jin C, Tan T, Guo Y. Optimal threshold in low-dose CT quantification of emphysema. *Eur J Radiol*. 2020;129:109094.
- Guan Y, Xia Y, Fan L, et al. Quantitative assessment of pulmonary perfusion using dynamic contrast-enhanced CT in patients with chronic obstructive pulmonary disease: correlations with pulmonary function test and CT volumetric parameters. *Acta Radiol*. 2015;56:573-580.
- Qin S, Yu X, Ma Q, et al. Quantitative CT analysis of small airway remodeling in patients with chronic obstructive pulmonary disease by a new image post-processing system. *Int J Chron Obstruct Pulmon Dis*. 2021;16:535-544.
- Wang G, Wang L, Ma Z, Zhang C, Deng K. Quantitative emphysema assessment of pulmonary function impairment by computed tomography in chronic obstructive pulmonary disease. *J Comput Assist Tomogr*. 2015;39:171-175.
- Wei X, Ma Z, Yu N, et al. Risk factors predict frequent hospitalization in patients with acute exacerbation of COPD. *Int J Chron Obstruct Pulmon Dis*. 2018;13:121-129.
- Zhu Y, Wang Z, Chen X, et al. Small pulmonary vascular alteration and acute exacerbations of COPD: quantitative computed tomography analysis. *Int J Chron Obstruct Pulmon Dis*. 2016;11:1965-1971.
- Zhang D, Guan Y, Zhou X, et al. Aerodynamic simulation of small airway resistance: a new imaging biomarker for chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2024;19:1167-1175.

32. Wang K, Wu F, He H, et al. Association between computed tomography-quantified respiratory muscles and chronic obstructive pulmonary disease: a retrospective study. *BMC Pulm Med*. 2024;24:150.
33. Wen X, Deng Z, Peng J, et al. Characteristics of inflammatory phenotypes in patients with chronic obstructive pulmonary disease: a cross-sectional study. *BMJ Open Respir Res*. 2023; 10:e001454.
34. Liu Y, Lu C, Chen W, et al. Clinical evaluation of pulmonary quantitative computed tomography parameters for diagnosing eosinophilic chronic obstructive pulmonary disease: characteristics and diagnostic performance. *Health Sci Rep*. 2024;7:e1734.
35. Zhou T, Guan Y, Lin X, et al. A clinical-radiomics nomogram based on automated segmentation of chest CT to discriminate PRISm and COPD patients. *Eur J Radiol Open*. 2024; 13:100580.
36. Guan Y, Zhang D, Zhou X, et al. Comparison of deep-learning and radiomics-based machine-learning methods for the identification of chronic obstructive pulmonary disease on low-dose computed tomography images. *Quant Imaging Med Surg*. 2024; 14:2485-2498.
37. Tan L, Yang X, Zhang J, Zhou K. Correlation between HIF1-A expression and airway remodeling in COPD. *Int J Chron Obstruct Pulmon Dis*. 2024;19:921-931.
38. Zhou TH, Zhou XX, Ni J, et al. CT whole lung radiomic nomogram: a potential biomarker for lung function evaluation and identification of COPD. *Mil Med Res*. 2024;11:14.
39. Zhou T, Guan Y, Lin X, et al. CT-based whole lung radiomics nomogram for identification of PRISm from non-COPD subjects. *Respir Res*. 2024;25:329.
40. Lin X, Zhou T, Ni J, et al. CT-based whole lung radiomics nomogram: a tool for identifying the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease. *Eur Radiol*. 2024;34:4852-4863.
41. Zhu Z, Zhao S, Li J, et al. Development and application of a deep learning-based comprehensive early diagnostic model for chronic obstructive pulmonary disease. *Respir Res*. 2024;25:167.
42. Lu D, Yu H, Chen L, Lin J, Chen S, Huang Y. Differences in the quantitative HRCT characteristics of patients with asthma, COPD and Asthma-COPD overlap and their relationships with pulmonary function. *Int J Chron Obstruct Pulmon Dis*. 2024; 19:1775-1789.
43. Zhang W, Zhao Y, Tian Y, Liang X, Piao C. Early diagnosis of High-Risk chronic obstructive pulmonary disease based on quantitative high-resolution computed tomography measurements. *Int J Chron Obstruct Pulmon Dis*. 2023;18:3099-3114.
44. Liu Y, Jiang Y, Sun Y. Interstitial lung abnormality in COPD is associated with higher prevalence of antinuclear antibody. *Expert Rev Respir Med*. 2023;17:735-742.
45. Feng S, Zhang R, Zhang W, et al. Predicting acute exacerbation phenotype in chronic obstructive pulmonary disease patients using VGG-16 deep learning. *Respiration*. 2025;104:1-14.
46. Wu J, Lu Y, Dong S, Wu L, Shen X. Predicting COPD exacerbations based on quantitative CT analysis: an external validation study. *Front Med (Lausanne)*. 2024;11:1370917.
47. An P, Liu J, Yu M, Wang J, Wang Z. Predicting mixed venous oxygen saturation (SvO<sub>2</sub>) impairment in COPD patients using clinical-CT radiomics data: a preliminary study. *Technol Health Care*. 2024;32:1569-1582.
48. Hu WT, Chen W, Zhou M, et al. Quantitative analyzes of the variability in airways via four-dimensional dynamic ventilation CT in patients with chronic obstructive pulmonary disease: correlation with spirometry data and severity of airflow limitation. *J Thorac Dis*. 2023;15:4775-4786.
49. Pu Y, Zhou X, Zhang D, et al. Quantitative assessment characteristics of small pulmonary vessel remodelling in populations at high risk for COPD and smokers using Low-Dose CT. *Int J Chron Obstruct Pulmon Dis*. 2024;19:51-62.
50. Zhu L, Liu J, Zeng L, et al. Thoracic high resolution computed tomography evaluation of imaging abnormalities of 108 lung cancer patients with different pulmonary function. *Cancer Imaging*. 2024;24:78.
51. Xie W, Fang Y, Yang G, Yu K, Li W. Transformer-Based Multi-Modal data fusion method for COPD classification and physiological and biochemical indicators identification. *Biomolecules*. 2023;13: 1391.
52. Nam JG, Witanto JN, Park SJ, Yoo SJ, Goo JM, Yoon SH. Automatic pulmonary vessel segmentation on noncontrast chest CT: deep learning algorithm developed using spatiotemporally matched virtual noncontrast images and low-keV contrast-enhanced vessel maps. *Eur Radiol*. 2021;31:9012-9021.
53. Chung MH, Gil BM, Kwon SS, et al. Computed tomographic thoracic morphologic indices in normal subjects and patients with chronic obstructive pulmonary disease: comparison with spiral CT densitometry and pulmonary function tests. *Eur J Radiol*. 2018;100:147-153.
54. Park H, Hwang EJ, Goo JM. Deep learning-based kernel adaptation enhances quantification of emphysema on low-dose chest CT for predicting long-term mortality. *Invest Radiol*. 2024; 59:278-286.
55. Kim EY, Seo JB, Lee HJ, et al. Detailed analysis of the density change on chest CT of COPD using non-rigid registration of inspiration/expiration CT scans. *Eur Radiol*. 2015;25:541-549.
56. Bak SH, Kim JH, Jin H, et al. Emphysema quantification using low-dose computed tomography with deep learning-based kernel conversion comparison. *Eur Radiol*. 2020;30:6779-6787.
57. Choe J, Choi HY, Lee SM, et al. Evaluation of retrieval accuracy and visual similarity in content-based image retrieval of chest CT for obstructive lung disease. *Sci Rep*. 2024;14:4587.
58. Sin S, Choi H-M, Lim J, et al. A genome-wide association study of quantitative computed tomographic emphysema in Korean populations. *Sci Rep*. 2021;11:16692.
59. Kim M, Doganay O, Hwang HJ, Seo JB, Gleeson FV. Lobar ventilation in patients with COPD assessed with the full-scale airway network flow model and xenon-enhanced dual-energy CT. *Radiology*. 2021;298:201-209.
60. Jin KN, Lee HJ, Park H, et al. Mucus plugs as precursors to exacerbation and lung function decline in COPD patients. *Arch Bronconeumol*. 2025;61:138-146.
61. Lee CW, Seo JB, Lee Y, et al. A pilot trial on pulmonary emphysema quantification and perfusion mapping in a single-step using contrast-enhanced dual-energy computed tomography. *Invest Radiol*. 2012;47:92-97.
62. Kim YW, Lee C-H, Hwang H-G, et al. Resting hyperinflation and emphysema on the clinical course of COPD. *Sci Rep*. 2019;9:3764.
63. Lee JS, Ra SW, Chae EJ, et al. Validation of the lower limit of normal diffusing capacity for detecting emphysema. *Respiration*. 2011;81:287-293.
64. Shima H, Tanabe N, Oguma A, et al. Subtyping emphysematous COPD by respiratory volume change distributions on CT. *Thorax*. 2023;78:344-353.
65. Lee SM, Seo JB, Hwang HJ, et al. Assessment of regional emphysema, air-trapping and Xenon-ventilation using dual-energy computed tomography in chronic obstructive pulmonary disease patients. *Eur Radiol*. 2017;27:2818-2827.
66. Ohara T, Hirai T, Sato S, et al. Comparison of airway dimensions in different anatomic locations on chest CT in patients with COPD. *Respirology*. 2006;11:579-585.
67. Tanabe N, Shima H, Sato S, et al. Direct evaluation of peripheral airways using ultra-high-resolution CT in chronic obstructive pulmonary disease. *Eur J Radiol*. 2019;120:108687.
68. Tanabe N, Muro S, Tanaka S, et al. Emphysema distribution and annual changes in pulmonary function in male patients with chronic obstructive pulmonary disease. *Respir Res*. 2012;13:31.
69. Tanabe N, Muro S, Hirai T, et al. Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2011;183:1653-1659.

70. Kinose D, Ogawa E, Kawashima S, et al. An index of the fractal characteristic of an airway tree is associated with airflow limitations and future body mass index reduction in COPD patients. *J Appl Physiol* (1985). 2020;128:1280-1286.
71. Takayanagi S, Kawata N, Tada Y, et al. Longitudinal changes in structural abnormalities using MDCT in COPD: do the CT measurements of airway wall thickness and small pulmonary vessels change in parallel with emphysematous progression? *COPD*. 2017;12:551-560.
72. Suzuki Y, Yoshimura K, Uto T, Sato J, Imokawa S, Suda T. Morphological changes in small pulmonary vessels are associated with severe acute exacerbation in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2016;11:1435-1445.
73. Matsuo Y, Ogawa E, Seto-Yukimura R, et al. Novel respiratory Impedance-Based phenotypes reflect different pathophysiologies in chronic obstructive pulmonary disease patients. *Int J Chron Obstruct Pulmon Dis*. 2019;14:2971-2977.
74. Shimizu K, Tanabe N, Tho NV, et al. Per cent low attenuation volume and fractal dimension of low attenuation clusters on CT predict different long-term outcomes in COPD. *Thorax*. 2020; 75:116-122.
75. Koyama H, Ohno Y, Yamazaki Y, et al. Quantitative bronchial luminal volumetric assessment of pulmonary function loss by thin-section MDCT in pulmonary emphysema patients. *Eur J Radiol*. 2012;81:384-388.
76. Muramatsu S, Sato K, Yamashiro T, Doi K. Quantitative measurements of emphysema in ultra-high resolution computed tomography using model-based iterative reconstruction in comparison to that using hybrid iterative reconstruction. *Phys Eng Sci Med*. 2022;45:115-124.
77. Yasuura Y, Terada Y, Mizuno K, et al. Quantitative severity of emphysema is related to the prognostic outcome of early-stage lung cancer. *Eur J Cardiothorac Surg*. 2022;62:ezac499.
78. Tanabe N, Sato S, Muro S, et al. Regional lung deflation with increased airway volume underlies the functional response to bronchodilators in chronic obstructive pulmonary disease. *Physiol Rep*. 2019;7:e14330.
79. Shiraishi Y, Tanabe N, Shimizu K, et al. Stronger associations of centrilobular than paraseptal emphysema with longitudinal changes in diffusing capacity and mortality in COPD. *Chest*. 2023;164:327-338.
80. Kumar I, Verma A, Jain A, Agarwal SK. Performance of quantitative CT parameters in assessment of disease severity in COPD: a prospective study. *Indian J Radiol Imaging*. 2018;28:99-106.
81. Chauhan NS, Sood D, Takkar P, Dhadwal DS, Kapila R. Quantitative assessment of airway and parenchymal components of chronic obstructive pulmonary disease using thin-section helical computed tomography. *Pol J Radiol* 2019;84:e54-e60.
82. Shaikh M, Sood RG, Sarkar M, Thakur V. Quantitative computed tomography (CT) assessment of emphysema in patients with severe chronic obstructive pulmonary disease (COPD) and its correlation with age, sex, pulmonary function tests, BMI, smoking, and biomass exposure. *Pol J Radiol*. 2017;82:760-766.
83. Tho NV, Ryujin Y, Ogawa E, et al. Relative contributions of emphysema and airway remodelling to airflow limitation in COPD: consistent results from two cohorts. *Respirology*. 2015; 20:594-601.
84. Lin Y, Sang L, Wang J, et al. Analysis of airway thickening and serum cytokines in COPD patients with frequent exacerbations: a heart of the matter. *Int J Chron Obstruct Pulmon Dis*. 2023; 18:2353-2364.
85. Li C, Lian X, He J, et al. Association of computed tomography-derived pectoralis muscle area and density with disease severity and respiratory symptoms in patients with chronic obstructive pulmonary disease: a case-control study. *Respir Med*. 2024; 233:107783.
86. Wu F, Jiang C, Zhou Y, et al. Association of total airway count on computed tomography with pulmonary function decline in early-stage COPD: a population-based prospective cohort study. *Int J Chron Obstruct Pulmon Dis*. 2021;16:3437-3448.
87. Karayama M, Inui N, Yasui H, et al. Clinical features of three-dimensional computed tomography-based radiologic phenotypes of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2019;14:1333-1342.
88. Li W, Meng H, Huang S, Lin H, Chen H. Computed tomography (CT) quantitative assessment of single lobe emphysema correlates with chronic obstructive pulmonary disease (COPD) severity: a cross-sectional study with retrospective data collection. *Quant Imaging Med Surg*. 2024;14:4540-4554.
89. Huang X, Yin W, Shen M, et al. Contributions of emphysema and functional small airway disease on intrapulmonary vascular volume in COPD. *Int J Chron Obstruct Pulmon Dis*. 2022; 17:1951-1961.
90. Chen H, Chen R-c, Guan Y-b, Li W, Liu Q, Zeng Q-s. Correlation of pulmonary function indexes determined by low-dose MDCT with spirometric pulmonary function tests in patients with chronic obstructive pulmonary disease. *Am J Roentgenol*. 2014;202:711-718.
91. Chen B, Liu Z, Lu J, et al. Deep learning parametric response mapping from inspiratory chest CT scans: a new approach for small airway disease screening. *Respir Res*. 2023;24:299.
92. Zhou X, Pu Y, Zhang D, et al. Development of machine learning model to predict pulmonary function with low-dose CT-derived parameter response mapping in a community-based chest screening cohort. *J Appl Clin Med Phys*. 2023;24:e14171.
93. Pu J, Zhou MJ, Shao JW, et al. High resolution computerized tomography quantitative evaluation of the correlation between central airway and pulmonary function grading in chronic obstructive pulmonary disease. *J Biol Regul Homeost Agents*. 2021; 35:1067-1072.
94. Li K, Gao Y, Pan Z, et al. Influence of emphysema and air trapping heterogeneity on pulmonary function in patients with COPD. *Int J Chron Obstruct Pulmon Dis*. 2019;14:2863-2872.
95. Wen X, Wu X, Deng Z, et al. The nonlinear relationship between High-Density lipoprotein and changes in pulmonary structure function and pulmonary function in COPD patients in China. *Int J Chron Obstruct Pulmon Dis*. 2024;19:1801-1812.
96. Chen H, Chen G-q, Zeng Q-s, Xia T-t, Zhou J-x, Qiu S-j. Quantitative assessment of airway pathology in subjects with COPD using low-dose high-resolution computed tomography. *Respir Care*. 2017;62:953-962.
97. Chen H, Zeng Q-s, Zhang M, et al. Quantitative Low-Dose computed tomography of the lung parenchyma and airways for the differentiation between chronic obstructive pulmonary disease and asthma patients. *Respiration*. 2017;94:366-374.
98. Xu Y, Liang T, Ma Y, et al. Strain analysis in patients at High-Risk for COPD using four-dimensional dynamic-ventilation CT. *Int J Chron Obstruct Pulmon Dis*. 2022;17:1121-1130.
99. Wang X, Duan J, Du Y, Shen N, He B, Yuan H. Trapping volumetric measurement by multidetector CT in chronic obstructive pulmonary disease: effect of CT threshold. *Med Phys*. 2013; 40:082103.
100. Wu Y, Zhao S, Qi S, et al. Two-stage contextual transformer-based convolutional neural network for airway extraction from CT images. *Artif Intell Med*. 2023;143:102637.
101. Hwang HJ, Seo JB, Lee SM, et al. Assessment of regional xenon ventilation, perfusion, and ventilation-perfusion mismatch using dual-energy computed tomography in chronic obstructive pulmonary disease patients. *Invest Radiol*. 2016;51:306-315.
102. Ho TT, Kim T, Kim WJ, et al. A 3D-CNN model with CT-based parametric response mapping for classifying COPD subjects. *Sci Rep*. 2021;11:34.
103. Koo H-K, Jin KN, Kim DK, Chung HS, Lee C-H. Association of incidental emphysema with annual lung function decline and future development of airflow limitation. *Int J Chron Obstruct Pulmon Dis*. 2016;11:161-166.

104. Im Y, Lee K, Lee SM, et al. Causal inference analysis of the radiologic progression in the chronic obstructive pulmonary disease. *Sci Rep*. 2024;14:17838.
105. Kim J, Kim B, Bak SH, Oh Y-M, Kim WJ. A comparative study of chest CT findings regarding the effects of regional dust exposure on patients with COPD living in urban areas and rural areas near cement plants. *Respir Res*. 2021;22:43.
106. Kang HS, Bak SH, Oh HY, et al. Computed tomography-based visual assessment of chronic obstructive pulmonary disease: comparison with pulmonary function test and quantitative computed tomography. *J Thorac Dis*. 2021;13:1495-1506.
107. Cappello F, Chung KS, Kim YS, et al. Functional and prognostic implications of the main pulmonary artery diameter to aorta diameter ratio from chest computed tomography in Korean COPD patients. *PLoS One*. 2016;11:e0154584.
108. Hwang J, Oh Y-M, Lee M, et al. Low morphometric complexity of emphysematous lesions predicts survival in chronic obstructive pulmonary disease patients. *Eur Radiol*. 2019;29:176-185.
109. Park J, Kim E-K, Lee SH, et al. Phenotyping COPD patients with emphysema distribution using quantitative CT measurement; more severe airway involvement in lower dominant emphysema. *Int J Chron Obstruct Pulmon Dis*. 2022;17:2013-2025.
110. Park SW, Lim M-N, Kim WJ, Bak SH. Quantitative assessment the longitudinal changes of pulmonary vascular counts in chronic obstructive pulmonary disease. *Respir Res*. 2022;23:29.
111. Bak SH, Kim S, Hong Y, Heo J, Lim M-N, Kim WJ. Quantitative computed tomography features and clinical manifestations associated with the extent of bronchiectasis in patients with moderate-to-severe COPD. *Int J Chron Obstruct Pulmon Dis*. 2018;13:1421-1431.
112. Jou SS, Yagihashi K, Zach JA, Lynch D, Suh YJ, COPDGene Investigators. Relationship between current smoking, visual CT findings and emphysema index in cigarette smokers. *Clin Imaging*. 2019;53:195-199.
113. Oh SY, Lee M, Seo JB, et al. Size variation and collapse of emphysema holes at inspiration and expiration CT scan: evaluation with modified length scale method and image co-registration. *Int J Chron Obstruct Pulmon Dis*. 2017;12:2043-2057.
114. Lee HJ, Seo JB, Chae EJ, et al. Tracheal morphology and collapse in COPD: correlation with CT indices and pulmonary function test. *Eur J Radiol*. 2011;80:e531-e535.
115. Xu Y, Yamashiro T, Moriya H, et al. Strain measurement on four-dimensional dynamic-ventilation CT: quantitative analysis of abnormal respiratory deformation of the lung in COPD. *Int J Chron Obstruct Pulmon Dis*. 2019;14:65-72.
116. Matsuoka S, Kurihara Y, Yagihashi K, Hoshino M, Nakajima Y. Airway dimensions at inspiratory and expiratory multisection CT in chronic obstructive pulmonary disease: correlation with airflow limitation. *Radiology*. 2008;248:1042-1049.
117. Tanabe N, Sato S, Oguma T, et al. Associations of airway tree to lung volume ratio on computed tomography with lung function and symptoms in chronic obstructive pulmonary disease. *Respir Res*. 2019;20:77.
118. Mochizuki E, Kawai Y, Morikawa K, et al. Difference in local lung movement during tidal breathing between COPD patients and asthma patients assessed by four-dimensional dynamic-ventilation CT scan. *Int J Chron Obstruct Pulmon Dis*. 2020;15:3013-3023.
119. Matsuo Y, Ogawa E, Tsunoda Y, et al. Inspiratory and expiratory computed tomography imaging clusters reflect functional characteristics in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2023;18:1047-1055.
120. Shima H, Tanabe N, Sato S, et al. Lobar distribution of non-emphysematous gas trapping and lung hyperinflation in chronic obstructive pulmonary disease. *Respir Investig*. 2020;58:246-254.
121. Ohara T, Hirai T, Sato S, et al. Longitudinal study of airway dimensions in chronic obstructive pulmonary disease using computed tomography. *Respirology*. 2008;13:372-378.
122. Okajima Y, Come CE, Nardelli P, et al. Luminal plugging on chest CT scan: association with lung function, quality of life, and COPD clinical phenotypes. *Chest*. 2020;158:121-130.
123. Ohno Y, Aoyagi K, Takenaka D, et al. Machine learning for lung CT texture analysis: improvement of inter-observer agreement for radiological finding classification in patients with pulmonary diseases. *Eur J Radiol*. 2021;134:109410.
124. Nagatani Y, Murata K, Takahashi M, et al. A new quantitative index of lobar air trapping in chronic obstructive pulmonary disease (COPD): comparison with conventional methods. *Eur J Radiol*. 2015;84:963-974.
125. Nishio M, Matsumoto S, Tsubakimoto M, et al. Paired inspiratory/expiratory volumetric CT and deformable image registration for quantitative and qualitative evaluation of airflow limitation in smokers with or without COPD. *Acad Radiol*. 2015;22:330-336.
126. Matsuoka S, Kurihara Y, Yagihashi K, Hoshino M, Watanabe N, Nakajima Y. Quantitative assessment of air trapping in chronic obstructive pulmonary disease using inspiratory and expiratory volumetric MDCT. *AJR Am J Roentgenol*. 2008;190:762-769.
127. Matsuura Y, Kawata N, Yanagawa N, et al. Quantitative assessment of cross-sectional area of small pulmonary vessels in patients with COPD using inspiratory and expiratory MDCT. *Eur J Radiol*. 2013;82:1804-1810.
128. Matsuoka S, Kurihara Y, Yagihashi K, Nakajima Y. Quantitative assessment of peripheral airway obstruction on paired expiratory/inspiratory thin-section computed tomography in chronic obstructive pulmonary disease with emphysema. *J Comput Assist Tomogr*. 2007;31:384-389.
129. Akira M, Toyokawa K, Inoue Y, Arai T. Quantitative CT in chronic obstructive pulmonary disease: inspiratory and expiratory assessment. *AJR Am J Roentgenol*. 2009;192:267-272.
130. Xu Y, Yamashiro T, Moriya H, Muramatsu S, Murayama S. Quantitative emphysema measurement on ultra-high-resolution CT scans. *Int J Chron Obstruct Pulmon Dis*. 2019;14:2283-2290.
131. Loh L-C, Ong C-K, Koo HJ, et al. A novel CT-emphysema index/FeV1 approach of phenotyping COPD to predict mortality. *Int J Chron Obstruct Pulmon Dis*. 2018;13:2543-2550.
132. Zhang L, Jiang B, Wisselink HJ, Vliegenthart R, Xie X. COPD identification and grading based on deep learning of lung parenchyma and bronchial wall in chest CT images. *Br J Radiol*. 2022;95:20210637.
133. Lu J, Ge H, Qi L, et al. Subtyping preserved ratio impaired spirometry (PRISm) by using quantitative HRCT imaging characteristics. *Respir Res*. 2022;23:309.
134. Yun J, Cho YH, Lee SM, et al. Deep radiomics-based survival prediction in patients with chronic obstructive pulmonary disease. *Sci Rep*. 2021;11:15144.
135. Park J, Yun J, Kim N, et al. Fully automated lung lobe segmentation in volumetric chest CT with 3D U-Net: validation with intra- and extra-datasets. *J Digit Imaging*. 2020;33:221-230.
136. Cho YH, Seo JB, Lee SM, et al. Radiomics approach for survival prediction in chronic obstructive pulmonary disease. *Eur Radiol*. 2021;31:7316-7324.
137. Aslan E, Kaya F, Özgül E, Balci A, Demirel E, Günay E. Quantitative computed tomography analysis of emphysema severity and distribution in chronic obstructive lung disease, correlation with clinical findings. *Tuberk Toraks*. 2021;69:338-348.
138. Zhang C, Liu J, Cao L, et al. Deep learning-based computed tomography features in evaluating early screening and risk factors for chronic obstructive pulmonary disease. *Contrast Media Mol Imaging*. 2022;2022:5951418.
139. Kurashima K, Hoshi T, Takaku Y, et al. Changes in the airway lumen and surrounding parenchyma in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2013;8:523-532.
140. Hasegawa M, Nasuhara Y, Onodera Y, et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2006;173:1309-1315.

141. Fujimoto K, Kitaguchi Y, Kubo K, Honda T. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. *Respirology*. 2006; 11:731-740.
142. Haruna A, Muro S, Nakano Y, et al. CT scan findings of emphysema predict mortality in COPD. *Chest*. 2010;138:635-640.
143. Kurashima K, Takayanagi N, Sato N, et al. High resolution CT and bronchial reversibility test for diagnosing COPD. *Respirology*. 2005;10:316-322.
144. Kurashima K, Takaku Y, Hoshi T, et al. Lobe-based computed tomography assessment of airway diameter, airway or vessel number, and emphysema extent in relation to the clinical outcomes of COPD. *Int J Chron Obstruct Pulmon Dis*. 2015; 10:1027-1033.
145. Matsuoka S, Washko GR, Yamashiro T, et al. Pulmonary hyper-tension and computed tomography measurement of small pulmonary vessels in severe emphysema. *Am J Respir Crit Care Med*. 2010;181:218-225.
146. Saruya S, Matsuoka S, Yamashiro T, et al. Quantitative CT measurements of small pulmonary vessels in chronic obstructive pulmonary disease: do they change on follow-up scans? *Clin Physiol Funct Imaging*. 2016;36:211-217.
147. Daimon T, Fujimoto K, Tanaka K, et al. Volume of pulmonary lobes and segments in chronic obstructive pulmonary diseases calculated using newly developed three-dimensional software. *Jpn J Radiol*. 2009;27:115-122.
148. Lee Y, Seo JB, Lee JG, Kim SS, Kim N, Kang SH. Performance testing of several classifiers for differentiating obstructive lung diseases based on texture analysis at high-resolution computerized tomography (HRCT). *Comput Methods Programs Biomed*. 2009;93:206-215.
149. Eom JS, Lee G, Lee HY, et al. The relationships between tracheal index and lung volume parameters in mild-to-moderate COPD. *Eur J Radiol*. 2013;82:e867-e872.
150. Zuo W, Li J, Zuo M, Li M, Zhou S, Cai X. Prediction of the benign and malignant nature of masses in COPD background based on habitat-based enhanced CT radiomics modeling: a preliminary study. *Technol Health Care*. 2024;32:2769-2781.
151. Shimizu K, Hasegawa M, Makita H, Nasuhara Y, Konno S, Nishimura M. Comparison of airway remodelling assessed by computed tomography in asthma and COPD. *Respir Med*. 2011; 105:1275-1283.
152. Yamada Y, Chubachi S, Yamada M, et al. Comparison of lung, lobe, and airway volumes between supine and upright computed tomography and their correlation with pulmonary function test in patients with chronic obstructive pulmonary disease. *Respiration*. 2022;101:1110-1120.
153. Mondoñedo JR, Sato S, Oguma T, et al. CT Imaging-based low-attenuation super clusters in three dimensions and the progression of emphysema. *Chest*. 2019;155:79-87.
154. Chubachi S, Yamada Y, Yamada M, et al. Differences in airway lumen area between supine and upright computed tomography in patients with chronic obstructive pulmonary disease. *Respir Res*. 2021;22:95.
155. Tanabe N, Muro S, Sato S, et al. Longitudinal study of spatially heterogeneous emphysema progression in current smokers with chronic obstructive pulmonary disease. *PLoS One*. 2012; 7:e44993.
156. Vasilescu DM, Martinez FJ, Marchetti N, et al. Noninvasive imaging biomarker identifies small airway damage in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2019;200:575-581.
157. Jin H, Heo C, Kim JH. Deep learning-enabled accurate normalization of reconstruction kernel effects on emphysema quantification in low-dose CT. *Phys Med Biol*. 2019;64:135010.
158. Park H, Yun J, Lee SM, et al. Deep learning-based approach to predict pulmonary function at chest CT. *Radiology*. 2023; 307:e221488.
159. Zhang L, Pelgrim GJ, Yan J, Zhang H, Vliegenthart R, Xie X. Feasibility of bronchial wall quantification in low- and ultralow-dose third-generation dual-source CT: an ex vivo lung study. *J Appl Clin Med Phys*. 2020;21:218-226.
160. Fang J, Li H, Liang M, Deng D, Zhou Q. Pulmonary dual hemodynamic changes in severe COPD patients: a quantitative study using low-dose CT lung perfusion scan. *I J Radiol*. 2019; 16:e68920.
161. Xia T, Zheng W, Lure FYM, Guan Y. CT phenotypes in mild-to-moderate chronic obstructive pulmonary disease: difference before and after the age of 60 years. *Clin Radiol*. 2021; 76:273-280.
162. Tanabe N, Muro S, Oguma T, et al. Computed tomography assessment of pharmacological lung volume reduction induced by bronchodilators in COPD. *COPD*. 2012;9:401-408.
163. Tanabe N, Sakamoto R, Kozawa S, et al. Deep learning-based reconstruction of chest ultra-high-resolution computed tomography and quantitative evaluations of smaller airways. *Respir Investig*. 2022;60:167-170.
164. Van Tho N, Ogawa E, Trang LTH, et al. A mixed phenotype of airway wall thickening and emphysema is associated with dyspnea and hospitalization for chronic obstructive pulmonary disease. *Ann Am Thorac Soc*. 2015;12:988-996.
165. Koyama H, Ohno Y, Nishio M, et al. Three-dimensional airway lumen volumetry: comparison with bronchial wall area and parenchymal densitometry in assessment of airway obstruction in pulmonary emphysema. *Br J Radiol*. 2012;85:1525-1532.
166. Pornsuriyasak P, Suwatanapongched T, Thaisuttikul W, et al. Assessment of proximal and peripheral airway dysfunction by computed tomography and respiratory impedance in asthma and COPD patients with fixed airflow obstruction. *Ann Thorac Med*. 2018;13:212-219.
167. Kim N, Seo JB, Lee Y, Lee JG, Kim SS, Kang S-H. Development of an automatic classification system for differentiation of obstructive lung disease using HRCT. *J Digit Imaging*. 2009; 22:136-148.
168. Nakano Y, Van Tho N, Yamada H, Osawa M, Nagao T. Radiological approach to asthma and COPD—the role of computed tomography. *Allergol Int*. 2009;58:323-331.
169. Zou C, Li F, Choi J, et al. Longitudinal Imaging-Based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS). *Int J Chron Obstruct Pulmon Dis*. 2021;16:1477-1496.
170. Ogawa E, Nakano Y, Ohara T, et al. Body mass index in male patients with COPD: correlation with low attenuation areas on CT. *Thorax*. 2009;64:20-25.
171. Lee HW, Lee J-K, Kim Y, et al. Differential decline of lung function in COPD patients according to structural abnormality in chest CT. *Heliyon*. 2024;10:e27683.
172. Yasui H, Inui N, Karayama M, et al. Correlation of the modified medical research council dyspnea scale with airway structure assessed by three-dimensional CT in patients with chronic obstructive pulmonary disease. *Respir Med*. 2019;146:76-80.
173. Xue M, Jia S, Chen L, Huang H, Yu L, Zhu W. CT-based COPD identification using multiple instance learning with two-stage attention. *Comput Methods Programs Biomed*. 2023;230:107356.
174. Xu C, Qi S, Feng J, et al. DCT-MIL: deep CNN transferred multiple instance learning for COPD identification using CT images. *Phys Med Biol*. 2020;65:145011.
175. Sun J, Liao X, Yan Y, et al. Detection and staging of chronic obstructive pulmonary disease using a computed tomography-based weakly supervised deep learning approach. *Eur Radiol*. 2022;32:5319-5329.
176. Li Z, Huang K, Liu L, Zhang Z. Early detection of COPD based on graph convolutional network and small and weakly labeled data. *Med Biol Eng Comput*. 2022;60:2321-2333.
177. Hatt CR, Oh AS, Obuchowski NA, Charbonnier JP, Lynch DA, Humphries SM. Comparison of CT lung density measurements

- between standard full-dose and reduced-dose protocols. *Radiol Cardiothorac Imaging*. 2021;3:e200503.
178. Ohno Y, Fujisawa Y, Fujii K, et al. Effects of acquisition method and reconstruction algorithm for CT number measurement on standard-dose CT and reduced-dose CT: a QIBA phantom study. *Jpn J Radiol*. 2019;37:399-411.
  179. Kubo T, Ohno Y, Nishino M, et al. Low dose chest CT protocol (50 mAs) as a routine protocol for comprehensive assessment of intrathoracic abnormality. *Eur J Radiol Open*. 2016;3:86-94.
  180. Lynch DA, Austin JHM, Hogg JC, et al. CT-Definable subtypes of chronic obstructive pulmonary disease: a statement of the Fleischner society. *Radiology*. 2015;277:192-205.
  181. Fan L, Xia Y, Guan Y, Zhang TF, Liu SY. Characteristic features of pulmonary function test, CT volume analysis and MR perfusion imaging in COPD patients with different HRCT phenotypes. *Clin Respir J*. 2014;8:45-54.
  182. Ohno Y, Takenaka D, Kanda T, et al. Adaptive iterative dose reduction using 3D processing for reduced- and low-dose pulmonary CT: comparison with standard-dose CT for image noise reduction and radiological findings. *AJR Am J Roentgenol*. 2012;199:W477-W485.
  183. Ley-Zaporozhan J, Ley S, Krummenauer F, Ohno Y, Hatabu H, Kauczor HU. Low dose multi-detector CT of the chest (iLEAD study): visual ranking of different simulated mAs levels. *Eur J Radiol*. 2010;73:428-433.
  184. Koyama H, Ohno Y, Yamazaki Y, et al. Quantitative and qualitative assessments of lung destruction and pulmonary functional loss from reduced-dose thin-section CT in pulmonary emphysema patients. *Acad Radiol*. 2010;17:163-168.
  185. Suzuki Y, Kitaguchi Y, Ueno F, et al. Associations between morphological phenotypes of COPD and clinical characteristics in surgically resected patients with COPD and concomitant lung cancer. *Int J Chron Obstruct Pulmon Dis*. 2022;17:1443-1452.
  186. Hasenstab KA, Yuan N, Retson T, et al. Automated CT staging of chronic obstructive pulmonary disease severity for predicting disease progression and mortality with a deep learning convolutional neural network. *Radiol Cardiothorac Imaging*. 2021;3:e200477.
  187. Nikolaou V, Massaro S, Garn W, Fakhimi M, Stergioulas L, Price D. The cardiovascular phenotype of chronic obstructive pulmonary disease (COPD): applying machine learning to the prediction of cardiovascular comorbidities. *Respir Med*. 2021;186:106528.
  188. Ying J, Dutta J, Guo N, et al. Classification of exacerbation frequency in the COPDGene cohort using deep learning with deep belief networks. *IEEE J Biomed Health Inform*. 2020;24:1805-1813.
  189. Humphries SM, Notary AM, Centeno JP, et al. Deep learning enables automatic classification of emphysema pattern at CT. *Radiology*. 2020;294:434-444.
  190. Lor KL, Liu CP, Chang YC, et al. Predictive modelling of lung function using emphysematous density distribution. *Sci Rep*. 2019;9:19763.
  191. Li Z, Xia Y, Fang Y, et al. The importance of CT quantitative evaluation of emphysema in lung cancer screening cohort with negative findings by visual evaluation. *Clin Respir J*. 2019;13:741-750.
  192. Xiuxiu Z, Yu P, Di Z, et al. Prediction of pulmonary function test parameters by parameter response mapping parameters based on random Forest regression model. *Chin J Radiol*. 2022;56:1001-1008.
  193. Chenwang J, Zhiran L, Haifeng D, et al. Establishment and preliminary application of a voxel-based method for the quantitative analysis of air trapping. *Chin J Radiol*. 2019;53:21-25.
  194. Xiaoqi H, Yuan N, Yu L, et al. Quantitative study on the degree of small airway disease and emphysema injury in pulmonary lobes of patients with smoking combined with chronic obstructive pulmonary disease based on biphasic CT. *Chin J Radiol*. 2022;56:536-541.
  195. Kim C, Lee KY, Shin C, et al. Comparison of filtered back projection, hybrid iterative reconstruction, model-based iterative reconstruction, and virtual monoenergetic reconstruction images at both low- and standard-dose settings in measurement of emphysema volume and airway wall thickness: a CT phantom study. *Korean J Radiol*. 2018;19:809-817.
  196. Chinese Society of Radiology of Chinese Medical Association. Chinese radiologist association, research center of clinical medical imaging of Anhui province: China expert consensus on clinical application of multi-energy CT. *Chin J Radiol*. 2022;56:476-487.